ClinVar Miner

Submissions for variant NM_024496.4(IRF2BPL):c.1267T>G (p.Tyr423Asp)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Pittsburgh Clinical Genomics Laboratory, University of Pittsburgh Medical Center RCV004784946 SCV005397217 uncertain significance Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures 2022-09-03 criteria provided, single submitter clinical testing This sequence variant is a single nucleotide substitution (T>G) at coding nucleotide 1267 of the IRF2BPL gene which results in a tyrosine to aspartic acid acid amino acid change at residue 423 in the IRF2BPL protein. This is a novel variant which has not been reported in clinical genetics databases or observed in the medical literature in individuals with IRF2BPL-related disease, to our knowledge. This variant is absent from the gnomAD control population dataset (0/~282000 alleles). Multiple bioinformatic tools predict that this protein change is likely to be damaging, and tyrosine is highly conserved at this protein position in vertebrates. Functiol studies testing the effects of this variant have not been performed, to our knowledge. At this time, there is insufficient evidence to determine if this variant is pathogenic or benign. Therefore, we consider it to be a variant of uncertain significance. ACMG Criteria: PM2, PP3

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.